Table 4.
Drug |
Pooled proportion
a
|
Hetetrogeneity |
|
|||
---|---|---|---|---|---|---|
p(95% CI) | Z- p | Q | Q -p | Q/df | I 2 | |
Amp |
98.68(94.85,99.67) |
0.000 |
0.09 |
0.954 |
0.05 |
0.0 |
Sxt |
98.68(94.85,99.67) |
0.000 |
0.09 |
0.954 |
0.05 |
0.0 |
Chl |
97.98(93.92,99.35) |
0.000 |
0.20 |
0.903 |
0.1 |
0.0 |
Cro |
97.98(93.92,99.35) |
0.000 |
0.20 |
0.903 |
0.1 |
0.0 |
MDR | 98.68(94.85,99.67) | 0.000 | 0.09 | 0.954 | 0.05 | 0.0 |
Amp = ampicillin; Chl = Chloramphenicol; Cro = ceftriaxone; df = degrees of freedom; Q = Cochran’s X2; Q-p = probability value of the Cochran’s Q test; Sxt = co-trimoxazole; Z-p = probability value of the Z test.
aThe estimates were based on four studies [13-15,41]. Data from two studies [14,41] were combined before pooling. Intermediate resistance to ciprofloxacin was recorded in twelve isolates [14,41].